992 related articles for article (PubMed ID: 1681750)
1. Dopamine in schizophrenia: a review and reconceptualization.
Davis KL; Kahn RS; Ko G; Davidson M
Am J Psychiatry; 1991 Nov; 148(11):1474-86. PubMed ID: 1681750
[TBL] [Abstract][Full Text] [Related]
2. Neuroleptics, dopamine, and schizophrenia.
Pickar D
Psychiatr Clin North Am; 1986 Mar; 9(1):35-48. PubMed ID: 2870480
[TBL] [Abstract][Full Text] [Related]
3. Effects of metabolic perturbation on plasma homovanillic acid in schizophrenia. Relationship to prefrontal cortex volume.
Breier A; Davis OR; Buchanan RW; Moricle LA; Munson RC
Arch Gen Psychiatry; 1993 Jul; 50(7):541-50. PubMed ID: 8317948
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of central dopamine receptors in schizophrenia.
Zemlan FP; Hitzemann RJ; Hirschowitz J; Garver DL
Am J Psychiatry; 1985 Nov; 142(11):1334-7. PubMed ID: 2865903
[TBL] [Abstract][Full Text] [Related]
5. Dopamine, the prefrontal cortex and schizophrenia.
Knable MB; Weinberger DR
J Psychopharmacol; 1997; 11(2):123-31. PubMed ID: 9208376
[TBL] [Abstract][Full Text] [Related]
6. Plasma homovanillic acid as an index of central dopaminergic activity: studies in schizophrenic patients.
Pickar D; Breier A; Kelsoe J
Ann N Y Acad Sci; 1988; 537():339-46. PubMed ID: 2904783
[TBL] [Abstract][Full Text] [Related]
7. Pathogenesis of schizophrenia: Part II. Temporo-frontal two-step hypothesis.
Kurachi M
Psychiatry Clin Neurosci; 2003 Feb; 57(1):9-15. PubMed ID: 12519449
[TBL] [Abstract][Full Text] [Related]
8. Neurobiology of dopamine in schizophrenia.
Guillin O; Abi-Dargham A; Laruelle M
Int Rev Neurobiol; 2007; 78():1-39. PubMed ID: 17349856
[TBL] [Abstract][Full Text] [Related]
9. Perspectives on a time-dependent model of neuroleptic action.
Pickar D
Schizophr Bull; 1988; 14(2):255-68. PubMed ID: 2904694
[TBL] [Abstract][Full Text] [Related]
10. Dopamine and schizophrenia.
Crow TJ; Johnstone EC; Longden A; Owen F
Adv Biochem Psychopharmacol; 1978; 19():301-9. PubMed ID: 29450
[No Abstract] [Full Text] [Related]
11. Dopamine in schizophrenia.
Heritch AJ
Am J Psychiatry; 1992 Nov; 149(11):1620-1. PubMed ID: 1415847
[No Abstract] [Full Text] [Related]
12. Do we still believe in the dopamine hypothesis? New data bring new evidence.
Abi-Dargham A
Int J Neuropsychopharmacol; 2004 Mar; 7 Suppl 1():S1-5. PubMed ID: 14972078
[TBL] [Abstract][Full Text] [Related]
13. New insights into the biology of schizophrenia through the mechanism of action of clozapine.
Brunello N; Masotto C; Steardo L; Markstein R; Racagni G
Neuropsychopharmacology; 1995 Nov; 13(3):177-213. PubMed ID: 8602893
[TBL] [Abstract][Full Text] [Related]
14. Persistent psychosis after reduction in pre- and post-synaptic dopaminergic function.
Wolkin A; Duncan E; Sanfilipo M; Wieland S; Cooper TB; Rotrosen J
J Neural Transm Gen Sect; 1994; 95(1):49-61. PubMed ID: 7857586
[TBL] [Abstract][Full Text] [Related]
15. [Hypofrontality and negative symptoms in schizophrenia: synthesis of anatomic and neuropsychological knowledge and ecological perspectives].
Semkovska M; Bédard MA; Stip E
Encephale; 2001; 27(5):405-15. PubMed ID: 11760690
[TBL] [Abstract][Full Text] [Related]
16. Dopamine receptors and the dopamine hypothesis of schizophrenia.
Seeman P
Synapse; 1987; 1(2):133-52. PubMed ID: 2905529
[TBL] [Abstract][Full Text] [Related]
17. [The involvement of 5-HT1a serotonin receptors in the pathophysiology and pharmacotherapy of schizophrenia].
Maćkowiak M; Czyrak A; Wedzony K
Psychiatr Pol; 2000; 34(4):607-21. PubMed ID: 11059260
[TBL] [Abstract][Full Text] [Related]
18. Neurochemical and neural mechanisms of positive and negative symptoms in schizophrenia.
Pickar D; Litman RE; Konicki PE; Wolkowitz OM; Breier A
Mod Probl Pharmacopsychiatry; 1990; 24():124-51. PubMed ID: 1970851
[TBL] [Abstract][Full Text] [Related]
19. [Biological markers in schizophrenia].
Lembreghts M; Ansseau M
Encephale; 1993; 19(5):501-23. PubMed ID: 8306920
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Correlation with psychosis and response to neuroleptic treatment.
Pickar D; Labarca R; Doran AR; Wolkowitz OM; Roy A; Breier A; Linnoila M; Paul SM
Arch Gen Psychiatry; 1986 Jul; 43(7):669-76. PubMed ID: 3718170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
